The Enterprise Value as of September 2024 (TTM) for Novo Nordisk A/S (NVO) is 4.01T

According to Novo Nordisk A/S’s latest financial reports and current stock price. The company's current Enterprise Value is 4.01T. This represents a change of 10.95% compared to the average of 3.62T of the last 4 quarters.

Novo Nordisk A/S (NVO) Historical Enterprise Value (quarterly & annually)

How has NVO Enterprise Value performed in the past?

The mean historical Enterprise Value of Novo Nordisk A/S over the last ten years is 1.18T. The current 4.01T Enterprise Value has changed 33.79% with respect to the historical average. Over the past ten years (40 quarters), NVO's Enterprise Value was at its highest in in the June 2024 quarter at 4.50T. The Enterprise Value was at its lowest in in the March 2017 quarter at 282.53B.

Novo Nordisk A/S (NVO) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Novo Nordisk A/S Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Novo Nordisk A/S (NVO) Average Enterprise Value

How has NVO Enterprise Value performed in the past?

The current Enterprise Value of Novo Nordisk A/S (NVO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Novo Nordisk A/S (NVO) Enterprise Value vs. Peers

How is NVO’s Enterprise Value compared to its peers?

Novo Nordisk A/S’s Enterprise Value is greater than Regeneron Pharmaceuticals, Inc. (123.45B), greater than CRISPR Therapeutics AG (3.55B), greater than Sarepta Therapeutics, Inc. (13.28B), greater than Intellia Therapeutics, Inc. (1.98B), greater than Moderna, Inc. (26.81B), greater than CureVac N.V. (390.67M), greater than Novavax, Inc. (1.40B), greater than CohBar, Inc. (-4942363.00), greater than Reata Pharmaceuticals, Inc. (6.68B), greater than BioNTech SE (9.15B), greater than Ginkgo Bioworks Holdings, Inc. (694.60M), greater than Vertex Pharmaceuticals Incorporated (117.15B), greater than BioMarin Pharmaceutical Inc. (16.13B), greater than Seagen Inc. (42.84B), greater than Alnylam Pharmaceuticals, Inc. (33.42B), greater than Madrigal Pharmaceuticals, Inc. (4.91B), greater than Intercept Pharmaceuticals, Inc. (915.81M), greater than TG Therapeutics, Inc. (3.44B), greater than Terns Pharmaceuticals, Inc. (458.36M), greater than Hepion Pharmaceuticals, Inc. (2.24M),

Build a custom stock screener for Novo Nordisk A/S (NVO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Novo Nordisk A/S using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Novo Nordisk A/S (NVO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Novo Nordisk A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.